Propel Health, a leading provider of strategic healthcare communications, has officially appointed Jeff Keller as President of its Medical Affairs division.
With over three decades of experience in healthcare communications, Keller is set to spearhead Propel Health’s ongoing initiatives in scientific engagement, medical strategy, and integrated communications solutions for pharmaceutical and biotech partners.
Health Technology Insights: Harmony Healthcare IT Names Brian Liddell President, CFO
“Jeff’s vision, operational acumen, and ability to marry strategy with execution make him the ideal candidate to guide our Medical Affairs business into its future,” said Propel Health CEO Mark Fleischer. “We are excited to have Jeff Keller join Propel Health.”
Before Propel, Keller was President of Citrus Scientific, where he effectively led the integration of four companies that were acquired and was a driving force behind increased organic and new business growth. Under his leadership, effective work was directed in challenging therapeutic areas including gene therapy, oncology, and neuroscience.
Health Technology Insights: Phoenix Heart Picks NextGen Healthcare to Boost Care and Revenue
His career also spans his senior positions at The Curry Rockefeller Group, ICON plc, and Complete Healthcare Communications Group (CHC) of MediMedia, where he time and again demonstrated his capability to grow high-performing teams and provide client-focused solutions. “I am thrilled to be joining Propel Health during this critical juncture,” added Keller. “The company’s devotion to excellence, innovation, and client partnership resonates strongly with my interest in medical affairs and scientific narrative. I am eager to work with the talented team at Propel to continue producing superior results for our clients and patients globally.” Keller graduated with a Bachelor of Science degree in Business Administration from the University of Denver.
Propel Health is a group of full-service healthcare communications firms specializing in medical affairs, digital engagement, launch strategy, and speaker bureau services. The company is recognized for therapeutic focus in rare disease, oncology, and specialty medicine, and collaborates closely with life sciences firms to make scientific information accessible, engaging, and impactful.
Health Technology Insights: Nymbl Appoints Josh Davidson as Chief Technology Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- businesswire
